
Gemma Shields

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9512546/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom. Pharmacoeconomics, 2022, 40, 65-76.	1.7	8
2	Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency. Pharmacoeconomics, 2022, 40, 149-156.	1.7	4
3	Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time. Pharmacoeconomics, 2022, 40, 249-256.	1.7	2
4	Utilising Patient and Public Involvement in Stated Preference Research in Health: Learning from the Existing Literature and a Case Study. Patient, 2021, 14, 399-412.	1.1	14
5	Delivery preferences for psychological intervention in cardiac rehabilitation: a pilot discrete choice experiment. Open Heart, 2021, 8, e001747.	0.9	7
6	Protocol for the economic evaluation of metacognitive therapy for cardiac rehabilitation participants with symptoms of anxiety and/or depression. BMJ Open, 2020, 10, e035552.	0.8	3
7	Real-world evidence use in assessments of cancer drugs by NICE. International Journal of Technology Assessment in Health Care, 2020, 36, 388-394.	0.2	23
8	A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. Journal of Medical Economics, 2020, 23, 1176-1185.	1.0	12
9	Challenges in synthesising cost-effectiveness estimates. Systematic Reviews, 2020, 9, 289.	2.5	46
10	Health State Values of Deaf British Sign Language (BSL) Users in the UK: An Application of the BSL Version of the EQ-5D-5L. Applied Health Economics and Health Policy, 2020, 18, 547-556.	1.0	1
11	Cost-Effectiveness Evaluations of Psychological Therapies for Schizophrenia and Bipolar Disorder: A Systematic Review. International Journal of Technology Assessment in Health Care, 2019, 35, 317-326.	0.2	14
12	A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments. Applied Health Economics and Health Policy, 2019, 17, 771-780.	1.0	32
13	Cognitive–behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. Health Technology Assessment, 2019, 23, 1-144.	1.3	16
14	Training to enhance user and carer involvement in mental health-care planning: the EQUIP research programme including a cluster RCT. Programme Grants for Applied Research, 2019, 7, 1-140.	0.4	8
15	Cost-effectiveness of cardiac rehabilitation: a systematic review. Heart, 2018, 104, 1403-1410.	1.2	208
16	A (five-)level playing field for mental health conditions?: exploratory analysis of EQ-5D-5L-derived utility values. Quality of Life Research, 2018, 27, 717-724.	1.5	9
17	Improving the effectiveness of psychological interventions for depression and anxiety in the cardiac rehabilitation pathway using group-based metacognitive therapy (PATHWAY Group MCT): study protocol for a randomised controlled trial. Trials, 2018, 19, 215.	0.7	37
18	Embedding shared decision-making in the care of patients with severe and enduring mental health problems: The EQUIP pragmatic cluster randomised trial. PLoS ONE, 2018, 13, e0201533.	1.1	33

#	Article	IF	CITATIONS
19	Cost-effectiveness of interventions for perinatal anxiety and/or depression: a systematic review. BMJ Open, 2018, 8, e022022.	0.8	30

Metacognitive therapy home-based self-help for cardiac rehabilitation patients experiencing anxiety and depressive symptoms: study protocol for a feasibility randomised controlled trial (PATHWAY) Tj ETQq0 0 0 rgBD/Dverlock310 Tf 50 d

21	A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union. BMJ Open, 2017, 7, e014847.	0.8	17
22	The Economic Value of Genetic Testing for Tolerance of Allopurinol in Gout. Journal of Rheumatology, 2017, 44, 717-719.	1.0	0
23	OP14â€A systematic review of cost-effectiveness evaluations of psychological therapies for schizophrenia and bipolar disorder. , 2017, , .		1
24	P75â€A cost-effectiveness analysis of improving access to psychological therapies in british sign language (bsl). , 2017, , .		0
25	Evaluating the effectiveness and cost-effectiveness of British Sign Language Improving Access to Psychological Therapies: an exploratory study. Health Services and Delivery Research, 2017, 5, 1-196.	1.4	12
26	Health related quality of life in the Deaf signing population. European Journal of Public Health, 2016, 26, .	0.1	0
27	Improving Access to Psychological Therapies in British Sign Language (BSL): A Cost-Effectiveness Analysis. Value in Health, 2016, 19, A525.	0.1	0
28	Health Related Quality of Life In The Deaf British Signing Population. Value in Health, 2016, 19, A571.	0.1	1
29	A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs, 2016, 30, 27-39.	2.7	90
30	A Systematic Review of the Cost Burden of Gout. Value in Health, 2015, 18, A656.	0.1	1
31	A Systematic Review of the Humanistic Burden of Gout. Value in Health, 2015, 18, A651.	0.1	0
32	A Systematic Review of the Economic and Humanistic Burden of Gout. Pharmacoeconomics, 2015, 33, 1029-1047.	1.7	49
33	Challenges for Assessing The Economic Value of Orphan Drugs - A Literature Review of Current And Alternative Approaches. Value in Health, 2015, 18, A681.	0.1	3
34	Antipsychotics for treatment of Pediatric Schizophrenia: a systematic review and network meta-analysis of Symptom control, Weight Gain and discontinuation due to adverse events. Value in Health, 2015, 18, A115-A116.	0.1	1
35	Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population. Applied Health Economics and Health Policy, 2015, 13, 543-551.	1.0	5
36	The Budget Impact Of New Generation Ct Scanners For Difficult-To-Image, Low-Risk Patients With Suspected Cad. Value in Health, 2014, 17, A479.	0.1	1

#	Article	IF	CITATIONS
37	The Move Towards Full Implementation Of The Nice Guidelines For Stroke Prevention In Atrial Fibrillation: The Potential Cost And Clinical Impact. Value in Health, 2014, 17, A480-A481.	0.1	1
38	Implementing home telehealth monitoring in patients with a chronic disease: a budget impact analysis. International Journal of Integrated Care, 2013, 13, .	0.1	1